NEUROBIOLOGICAL TECHNOLOGIES BEGINS SECOND VIPRINEX STROKE TRIAL

A A

Neurobiological Technologies has initiated its second Phase III study of Viprinex (Ancrod) in patients with acute ischemic stroke. The overall clinical development program for both trials will enroll 1,300 patients, divided equally between the two trials. The program will be global in nature recruiting patients in the U.S., Europe, the Pacific Rim, and South Africa.

The study is a randomized, double-blind, placebo-controlled trial of patients who will receive a brief intravenous infusion of Viprinex or placebo within six hours of the onset of stroke.